Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 7, 2020Blood AdvancesOpen Access

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

View Full Paper
Ask AI
Bookmark
Share

Authors

LVLinus A. VölkerUniversity of CologneJKJessica KaufeldBrigham and Women's HospitalWMWolfgang MiesbachGoethe University Frankfurt

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Völker et al. (2020) studied this question.

synapsesocial.com/papers/6a3f88c6b7b89a99a2fd675dhttps://doi.org/10.1182/bloodadvances.2020001973
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey2016 · 19 citations
  2. 2Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura2016 · 680 citations
  3. 3Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura2019 · 1,047 citations